Abstract: A calixarene compound in an antiviral effective amount for use as an antiviral substance in a pharmaceutical preparation for use in prophylactic or therapeutic treatment of a disease condition which is caused by or associated with an infection with a virus.

Abstract: An Azelastine compound in an antiviral effective amount for use as an antiviral substance in a pharmaceutical preparation for use in prophylactic or therapeutic treatment of a subject in need of antiviral treatment.

Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Abstract: Compounds of general Formula (I) wherein the elements A, L, R1 and R2 have a defined meaning, and their medical and non-medical use. The compounds may be used treatment of a subject in need of any one or more of anti-inflammatory, anti-oxidative, anti-ageing, or lipid metabolism modulation therapy or prophylaxis. The compounds may also be used as food or feed products, dietary supplements or cosmetic preparations.

Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.

Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.

Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.

Abstract: The present invention is directed to a compound for use in the prevention or treatment of a neurodegenerative disease, in particular of a synucleinopathy. The present invention further is directed to a pharmaceutical composition containing an effective amount of said compound and one or more pharmaceutically acceptable auxiliaries.

Abstract: The present invention is directed to a compound for use in the prevention or treatment of a neurodegenerative disease, in particular of a synucleinopathy. The present invention further is directed to a pharmaceutical composition containing an effective amount of said compound and one or more pharmaceutically acceptable auxiliaries.

Abstract: A method for measuring cross-relation rates in high-resolution nuclear magnetic resonance (NMR) spectroscopy in which in a homogeneous static magnetic field B.sub.0 in a direction of a z-axis which causes alignment of longitudinal components I.sub.Z.sup.A, I.sub.Z.sup.X of magnetization vectors I.sup.A, I.sup.X of nuclei A, X during a time interval .tau..sub.m a sample substance, preferably dissolved in liquid, with nuclei A and X having different chemical shifts .OMEGA..sub.A and .OMEGA..sub.X is irradiated with a radio-frequency (rf) field and afterwards by action of a suitable rf-pulse sequence the longitudinal magnetization is transferred into a transverse magnetization creating a rf-signal received by a detector, is characterized in that the rf field is composed by at least two weak, selective component fields, the frequencies of these fields being chosen such that the magnetization vectors I.sup.A and I.sup.